Company / EPS (Diluted)
Lexaria Bioscience Corp. EPS (Diluted) History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.47
FY2025
5-year range
-$1.47 / -$0.47
FY2021-FY2025
Trend
+53.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has fluctuated over the past 8 years, ranging from $-1.47 in FY2021 to $-0.03 in FY2017.
Based on SEC 10-K filings.
-0.47 in FY2025.
Improved from $-1.47 to $-0.47 over the past 4 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 53.5% year-over-year.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.47 | +53.5% |
| FY2024 | -$1.01 | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -$1.47 | -2840.0% |
| FY2020 | -$0.05 | +44.4% |
| FY2019 | -$0.09 | -200.0% |
| FY2017 | -$0.03 | +25.0% |
| FY2016 | -$0.04 | +71.4% |
| FY2015 | -$0.14 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026